Second Primary Malignancies in Patients with Well-differentiated/Dedifferentiated Liposarcoma

Eric Jung; Marco Fiore; Alessandro Gronchi; Valerie Grignol; Raphael E Pollock; Susan S Chong; Shefali Chopra; Ann S Hamilton; William W Tseng

doi:10.21873/anticanres.12625

Second Primary Malignancies in Patients with Well-differentiated/Dedifferentiated Liposarcoma

Anticancer Res. 2018 Jun;38(6):3535-3542. doi: 10.21873/anticanres.12625.

Authors

Eric Jung¹, Marco Fiore², Alessandro Gronchi², Valerie Grignol³, Raphael E Pollock³, Susan S Chong¹, Shefali Chopra⁴, Ann S Hamilton⁵, William W Tseng⁶

Affiliations

¹ Department of Surgery, University of Southern California, Keck School of Medicine, Los Angeles, CA, U.S.A.
² Department of Surgery, IRCCS Foundation National Tumor Institute, Milan, Italy.
³ Department of Surgery, The James Comprehensive Cancer Center, Ohio State University, Columbus, OH, U.S.A.
⁴ Discovery Research Program, Department of Pathology and Laboratory Medicine, University of Southern California, Los Angeles, CA, U.S.A.
⁵ Department of Preventive Medicine, University of Southern California, Keck School of Medicine, Los Angeles, CA, U.S.A.
⁶ Department of Surgery, University of Southern California, Keck School of Medicine, Los Angeles, CA, U.S.A. william.tseng@med.usc.edu.

Abstract

Background: Well-differentiated/dedifferentiated (WD/DD) liposarcoma is a rare malignancy of putative adipocyte origin. To our knowledge, there have only been isolated case reports describing second primary cancer in patients with this disease. We report on a combined case series of such patients and explore the frequency of this occurrence using a national cancer database.

Materials and methods: Demographics and clinicopathological data were collected from patients with WD/DD liposarcoma who were found to have a concurrent or subsequent second primary cancer, at one of three sarcoma referral centers from 2014-2016. The Surveillance, Epidemiology and End Results (SEER) database was also queried to identify adult patients diagnosed with WD/DD liposarcoma between 1973-2012. Observed/expected (O/E) ratios of second primary malignancies among these cases were calculated by comparison to the age-adjusted cancer incidence in the general population using SEER*stat software.

Results: In total, 26 out of 312 consecutive patients (8.3%) with WD/DD liposarcoma at our centers had a second primary cancer identified within 2 years of liposarcoma diagnosis. In the SEER database, among 1,845 patients with WD/DD liposarcoma, 75 (4.1%) had a second cancer within 2 years after liposarcoma diagnosis (O/E ratio=1.81, 99% confidence interval(CI)=1.33-2.40). Patients less than 50 years old at the time of liposarcoma diagnosis had a higher O/E ratio for second primary malignancy compared to older patients. A total of 269 patients (14.6%) developed a second cancer (O/E=1.33, 99% CI=1.15-1.54).

Conclusion: In some patients with WD/DD liposarcoma, there appears to be an increased risk of having a second primary cancer. Further validation and investigation is needed, as this finding may have implications (e.g. closer screening) for patients with this disease.

Keywords: Liposarcoma; epidemiology; second primary neoplasms; soft tissue sarcoma.

Publication types

Multicenter Study

MeSH terms

Adult
Aged
Aged, 80 and over
Female
Humans
Liposarcoma / complications*
Liposarcoma / diagnostic imaging
Male
Middle Aged
Neoplasms, Second Primary / complications*
Neoplasms, Second Primary / diagnostic imaging
Retroperitoneal Neoplasms / complications*
Retroperitoneal Neoplasms / diagnostic imaging
Time Factors
Tomography Scanners, X-Ray Computed

Grants and funding

P30 CA014089/CA/NCI NIH HHS/United States